AI Summary
✦ ClarthaDr. Lal PathLabs is a diagnostic laboratory company conducting pathological and radiological investigations in India and internationally. Biochemistry, hematology, and microbiology support core testing revenue, alongside histopathology and immunochemistry services. Phlebotomist training programs remain an ancillary offering. With no major recent development, revenue growth reached 12.3%, while stable margins indicate limited near-term operating leverage. Profit growth of 3.6% materially trails revenue, suggesting earnings conversion remains constrained despite stable margins. ROE is unavailable, while debt-to-equity of 7.83 indicates substantial leverage that can amplify reported returns and financial risk. At 60.1 times earnings, the stock appears rich and trades at a premium to its growth rate. The key open question is whether diagnostic volume growth can improve profit conversion without further leverage.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 26 analysts
Fundamentals
Fundamentals institutional score is 88 using growth durability 88.1.
Valuation
Valuation institutional score is 14 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 40 using mean target upside -1.1%; dispersion penalty 23.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 49 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 38.4% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.86). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹43.39. Applying the stock's normalized valuation corridor produces a fair range of ₹1,688.74 to ₹2,054.95, with base value near ₹1,865.77 (-4.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹43.39
Forward P/E
45.0x
Base Fair Value
₹1,865.77
Fair Range
₹1,688.74 - ₹2,054.95
Upside To Base
-4.5%
Estimate Source
Live forward EPS
Growth Estimate
+27.8%
5Y Average
41.50
Current
59.53
Overvalued
47.36
Undervalued
38.92
5Y Average
27.51
Current
39.91
Overvalued
31.02
Undervalued
23.66
5Y Average
7.79
Current
11.31
Overvalued
8.79
Undervalued
6.70
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 46.9x Undervalued | -43% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 68.7x Undervalued | -17% vs avg | +6.9% |
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 68.7x Undervalued | -17% vs avg | +1.4% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.1x Undervalued | -29% vs avg | +7.6% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 54.5x Undervalued | -34% vs avg | +12.9% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 138.6x Premium | +68% vs avg | +47.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 157.6x Premium | +91% vs avg | +10.2% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 65.0x Undervalued | -21% vs avg | +23.2% |
DR. LAL PATH LABS LTD. trades at a discount (60.1x vs peer avg 82.3x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include NARAYANA HRUDAYALAYA LTD., GLOBAL HEALTH LIMITED, FORTIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹764 CrJun 2026Latest net profit
₹166 CrJun 2026Latest EPS
₹9.90Jun 2026Net margin
31.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 480 | 532 | 476 | 521 | 574 | 631 | 569 | 577 | 641 | 700 | 632 | 675 | 764 |
| Expenses + | 344 | 369 | 346 | 383 | 413 | 437 | 418 | 418 | 457 | 484 | 458 | 494 | 526 |
| Operating Profit | 136 | 163 | 130 | 138 | 161 | 194 | 151 | 159 | 183 | 215 | 174 | 182 | 238 |
| OPM % | 28% | 31% | 27% | 26% | 28% | 31% | 27% | 28% | 29% | 31% | 27% | 27% | 31% |
| Other Income + | 15 | 14 | 15 | 16 | 31 | 24 | 31 | 25 | 26 | 23 | -4 | 37 | 30 |
| Interest | 7 | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 7 | 6 | 6 |
| Depreciation | 18 | 19 | 19 | 35 | 33 | 33 | 34 | 35 | 33 | 38 | 40 | 43 | 40 |
| Profit before tax | 125 | 151 | 120 | 113 | 154 | 179 | 144 | 145 | 172 | 195 | 123 | 170 | 222 |
| Tax % | 25% | 25% | 26% | 29% | 26% | 28% | 27% | -2% | 25% | 25% | 25% | 17% | 25% |
| Net Profit + | 94 | 113 | 88 | 81 | 114 | 129 | 105 | 148 | 129 | 146 | 92 | 141 | 166 |
| EPS in Rs | 5.61 | 6.77 | 5.29 | 4.84 | 6.86 | 7.71 | 6.30 | 8.88 | 7.71 | 8.69 | 5.50 | 8.42 | 9.90 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Earnings Call Transcript